impact factor, citescore
logo
In press
In Press
Recent issue
Recent issue
Recent Supplement
Recent supplement
archives
Archives
articles free
Free to view
Search
Search
 

Full Papers

 

Early treatment of psoriatic arthritis is associated with improved patient-reported outcomes: findings from the etanercept PRESTA trial

1, 2, 3, 4, 5, 6, 7

 

  1. Guy’s and St Thomas’ NHS Foundation Trust, London, UK.
  2. Katholieke Universiteit Leuven, Leuven, Belgium.
  3. Quintiles, Collegeville, PA, USA.
  4. Pfizer Inc, Collegeville, PA, USA.
  5. Pfizer Europe, Rome, Italy.
  6. Pfizer Europe, Rome, Italy.
  7. Pfizer Europe, Rome, Italy.

CER7008
2015 Vol.33, N°1
PI 0011, PF 0019
Full Papers

Free to view
(click on article PDF icon to read the article)

PMID: 25535650 [PubMed]

Received: 02/10/2013
Accepted : 29/04/2014
In Press: 22/12/2014
Published: 03/03/2015

Abstract

OBJECTIVES:
The present paper aims to investigate the effect of psoriatic arthritis (PsA) disease duration on the outcome of treatment with etanercept (ETN) in patients with PsA who also have moderate-to-severe psoriasis.
METHODS:
Patients from the PRESTA trial who received ≥1 ETN 50 mg once weekly (QW) dose and had ≥1 post-baseline value were evaluated. Baseline and after-treatment changes were compared between patients with PsA ≤2 years versus PsA >2 years in efficacy measures (physician global assessment [PGA] arthritis, swollen joint count and Psoriasis Area and Severity Index [PASI]) and patient reported outcomes (PROs; joint pain, arthritis activity, Euro-Qol [EQ-5D] utility and visual analogue score [VAS]) using linear regression analysis.
RESULTS:
Baseline efficacy measures were similar between the PsA ≤2 years (n=103) and PsA >2 years (n=269) groups, with the exception of PGA arthritis (p=0.006). At week 24, improvements in efficacy measures were observed in both groups but were significantly greater for PGA arthritis in the PsA ≤2 years group (p=0.03). Quality of life (QoL), measured using PROs, was generally lower at baseline in patients with PsA >2 years. Clinically meaningful improvements were seen in QoL with ETN treatment in both groups, but the change from baseline scores at week 24 were significantly higher in PsA ≤2 years group for joint pain (p=0.007), arthritis activity (p=0.01), EQ-5D utility (p=0.046) and EQ-5D VAS (p=0.04) responses.
CONCLUSIONS:
PsA patients responded to ETN 50 mg QW treatment irrespective of disease duration; however, patients with shorter PsA duration had greater improvements in arthritis scores and several PRO measures.

Rheumatology Article